What Happened?
Shares of medical device company Boston Scientific (NYSE:BSX) jumped 8.5% in the pre-market session after the company reported first quarter 2025 results that beat analysts' sales and EPS expectations. Organic sales growth topped the company's own forecast and was led by a 25.6% surge in its Cardiovascular segment, a signal that demand in its largest business is accelerating. Looking ahead, its revenue guidance for next quarter exceeded Wall Street's estimates. Overall, we think this was a decent quarter with some key metrics above expectations.
After the initial pop the shares cooled down to $99.43, up 4.7% from previous close.
Is now the time to buy Boston Scientific? Access our full analysis report here, it’s free.
What The Market Is Telling Us
Boston Scientific’s shares are not very volatile and have only had 4 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
Boston Scientific is up 11.2% since the beginning of the year, and at $99.43 per share, it is trading close to its 52-week high of $106.18 from February 2025. Investors who bought $1,000 worth of Boston Scientific’s shares 5 years ago would now be looking at an investment worth $2,732.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.